KALA BIO, Inc., founded in Arlington, Texas, is a clinical-stage biopharmaceutical company dedicated to addressing rare and serious eye diseases. The company's core mission is to develop innovative therapies that leverage advanced science to penetrate mucosal tissues such as the eyes, lungs, gastrointestinal tracts, and female reproductive systems. KALA BIO's primary focus is on the research and development of mesenchymal stem cell secretome (MSC-S) therapies, aiming to provide regenerative healing effects for ocular surface and retinal diseases, ultimately preserving vision.
Notable figures affiliated with KALA BIO include leading scientists and researchers in the field of biopharmaceuticals. The company has attracted significant investment from prominent venture capital firms specializing in healthcare and biotechnology. Key achievements include the successful development of their proprietary MSC-S platform and the progression of several therapies into clinical trials. KALA BIO's impact is marked by its potential to revolutionize treatment for rare eye diseases, offering hope and improved quality of life for patients worldwide.
